STOCK COMMENTS / EPS CHANGESArena Pharmaceuticals ( ARNA) numbers increased at BMO. ARNA estimates were raised through 2013, BMO Capital said. Company received better labeling in its FDA approval. Market Perform rating and new $12 price target. Arena Pharmaceuticals target raised at Jefferies. Shares of ARNA now seen reaching $20, Jefferies said. FDA approves Lorcaserin. Buy rating.
Monsanto ( MON) numbers raised at Citigroup. Shares of MON now seen reaching $93, Citigroup said. Estimates also increased on higher corn acres.Progress Software ( PRGS) target lowered at Jefferies. Shares of PRGS now seen reaching $25, Jefferies said. Transitional uncertainties. Hold rating. Radware ( RDWR) numbers raised at Oppenheimer. Shares of RDWR now seen reaching $45, Oppenheimer said. Estimates also raised on upside in September. Outperform rating. Riverbed ( RVBD) estimates, target reduced at JMP. RVBD estimates were cut through 2013, JMP Securities said. Company is facing a challenging environment and likely seeing higher turnover in its salesforce. Outperform rating and new $21 price target. Warnaco ( WRC) estimates, target cut at Credit Suisse. Shares of WRC now seen reaching $48, according to Credit Suisse. Estimates also reduced, given the company's exposure to Southern Europe. Neutral rating. >To submit a news tip, email: email@example.com.
Twitter and become a fan on Facebook.